Patents by Inventor Daniel J. Cua

Daniel J. Cua has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDL-1 ligand
    Patent number: 9284377
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Joseph H. Phillips
  • MDL-1 LIGAND
    Publication number: 20150368344
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Application
    Filed: June 19, 2015
    Publication date: December 24, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Maribel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Phillips
  • USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20140248279
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicants: Merck Sharp & Dohme Corp., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Modulation of PILR to Treat Immune Disorders
    Publication number: 20140234301
    Abstract: The present invention provides methods of using PILR? agonists, or PILR? antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Cristina M. Tato, Barbara Joyce-Shaikh, Daniel J. Cua
  • MDL-1 LIGAND
    Publication number: 20140227719
    Abstract: The invention provides methods for modulation interactions between MDL-1 and its binding partner, Gal9. Also provided are methods to screen for modulators of MDL-1/Gal9 interaction.
    Type: Application
    Filed: September 17, 2012
    Publication date: August 14, 2014
    Inventors: Barbara Joyce-Shaikh, Douglas C. Wilson, Daniel J. Cua, Drake M. LaFace, Marbel Beaumont, Holly Cherwinski, Mark Hsieh, Sabrina Benchaar, Joseph H. Philips
  • Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-?
    Patent number: 8691227
    Abstract: The present invention provides methods of using PILR? agonists, or PILR? antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cristina M. Tato, Barbara Joyce-Shaikh, Daniel J. Cua
  • USE OF MDL-1 ANTAGONISTS TO TREAT SPONDYLARTHROPATHY
    Publication number: 20130323246
    Abstract: The invention provides methods for treating spondylarthropathy with antagonists of MDL-1 alone or in combination with IL-23 antagonists.
    Type: Application
    Filed: February 14, 2012
    Publication date: December 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Barbara Joyce-Shaikh, Drake LaFace, Jonathan P. Sherlock
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20130323251
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicants: The Government of the United States of America as represented by the Secretary of the Dep. of H.H.S., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20130287775
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy L. Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
    Patent number: 8524230
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: September 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
  • MODULATION OF PILR TO TREAT IMMUNE DISORDERS
    Publication number: 20130071380
    Abstract: The present invention provides methods of using PILR? agonists, or PILR? antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 21, 2013
    Applicant: Schering Corporation
    Inventors: Cristina M. Tato, Barbara Joyce-Shaikh, Daniel J. Cua
  • Use of agonists and antagonists of IL-23 in the treatment of viral infection
    Patent number: 8263080
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating viral infections. Also provided are reagents for use in screening for agonists or antagonists of IL-23.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: September 11, 2012
    Assignee: Schering Corporation
    Inventors: Peter D. Katsikis, Ioannis Dimitriou, Daniel J. Cua
  • MDL-1 USES
    Publication number: 20120177647
    Abstract: The invention provides methods for treating bone resorption disorders with antagonists of MDL-1.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: Schering Corporation
    Inventors: Michael E. Bigler, Daniel J. Cua, Barbara Joyce-Shaikh, Joseph H. Phillips
  • Pathogenic TH17 Cells; related reagents and methods
    Publication number: 20120156699
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: February 24, 2012
    Publication date: June 21, 2012
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy Lynn Miller, Melanie A. Kleinschek, Katia Boniface, Kristian S. Bak-Jensen, Brent S. McKenzie, Rene de Waal Malefyt
  • USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS
    Publication number: 20120052044
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: November 1, 2011
    Publication date: March 1, 2012
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Methods of treating cutaneous ulcers and grafts using agonist antibodies to IL-23 receptor
    Patent number: 8062634
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: November 22, 2011
    Assignee: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20110142831
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: January 28, 2011
    Publication date: June 16, 2011
    Applicants: Schering Corporation, Department of Health and Human Services
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Uses of Mammalian Cytokine; Related Reagents
    Publication number: 20110135597
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Application
    Filed: February 14, 2011
    Publication date: June 9, 2011
    Applicant: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Agonist antibodies to IL-23 receptor
    Patent number: 7893215
    Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: February 22, 2011
    Assignee: Schering Corporation
    Inventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan
  • Uses of Mammalian Cytokine; Related Reagents
    Publication number: 20110002928
    Abstract: Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis.
    Type: Application
    Filed: September 17, 2010
    Publication date: January 6, 2011
    Applicant: Schering Corporation
    Inventors: Daniel J. Cua, Robert A. Kastelein